The DOI matches its Crossref record; 143 of the 147 references it cites were found in a registry or an index.
Inositols in PCOS
Open accessAbstract
(1) Background: Myoinositol (MI) and D-chiro-inositol (DCI) are involved in a number of biochemical pathways within oocytes having a role in oocyte maturation, fertilization, implantation, and post-implantation development. Both inositols have a role in insulin signaling and hormonal synthesis in the ovaries. (2) Methods: Literature search (with key words: inositols, myo-inositol, d-chiro-inositol, PCOS) was done in PubMed until Sept. 2020 and 197 articles were identified, of which 47 were of clinical trials (35 randomized controlled trials). (3) Results: Many studies have demonstrated that in patients with polycystic ovarian syndrome (PCOS) MI treatment improved ovarian function and fertility, decreased the severity of hyperandrogenism including acne and hirsutism, positively affected metabolic aspects, and modulated various hormonal parameters deeply involved in the reproductive axis function and ovulation. Thus treating with MI has become a novel method to ameliorate PCOS symptoms, improve spontaneous ovulation, or induce ovulation. The current review is focused on the effects of MI and DCI alone or in combination with other agents on the pathological features of PCOS with focus on insulin resistance and adverse metabolic outcomes. (4) Conclusions: The available clinical data suggest that MI, DCI, and their combination in physiological ratio 40:1 with or without other compound could be beneficial for improving metabolic, hormonal, and reproductive aspects of PCOS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 (a) Effects of myoinositol and D-chiroinositol on glucose metabolism in PCOS (adapted from [68]). (b) Effects of myoinositol and D-chiroinositol on hormonal synthesis in PCOS.](https://figures.cochat.ai/paper-figures/9dd0bedcafd0485a835f08372099aad1/inositols-in-pcos-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“On the other hand, insulin resistance (IR) has a central role in its pathogenesis [5–7].”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Papaleo, E., Unfer, V., Baillargeon, J.-P., Fusi, F., Occhi, F., & De Santis, L. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.01.088 · Cited by 197 · cited 1×
“The trials assessing this combination show improved reproductive [100], hormonal, and metabolic disturbances in PCOS patients [95,97,108,123].”
BackgroundRetracted- Retracted
Pacchiarotti, A., Carlomagno, G., Antonini, G., & Pacchiarotti, A. (2016) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1101444 · Cited by 111
RetractedRETRACTED: Treatment of hirsutism with myo-inositol: a prospective clinical study
Minozzi, M., D'Andrea, G., & Unfer, V. (2008) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)60248-9 · Cited by 56 · cited 2×
“Some studies have demonstrated that MI treatment in patients with PCOS improved ovarian function and fertility [98–109], decreased the severity of hyperandrogenism, acne, and hirsutism [78,96,102], and positively affected metabolic parameters and modulated various hormonal parameters deeply involved in the reproductiv…”
BackgroundMethodRetracted(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
The Diagnosis of Polycystic Ovary Syndrome during Adolescence
Witchel, S. F., Oberfield, S., Rosenfield, R. L., Codner, E., Bonny, A., Ibáñez, L., Pena, A., Horikawa, R., Gomez-Lobo, V., Joel, D., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000375530 · Cited by 3,113
Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis*
Dunaif, A. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0318 · Cited by 2,458 · cited 1×
“The patients with PCOS both with and without obesity have higher prevalence of insulin resistance compared to healthy controls [19], although insulin resistance is more severe in obese subjects [20].”
BackgroundAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143 · cited 2×
“The use of Rotterdam criteria is advised by the two recent guidelines [7,9] both recognizing that Androgen Excess Society (AES) [1] criteria may correspond better to the pathogenesis of this disorder, as the AES emphasizes the importance Molecules 2020, 25, 5566; doi:10.3390/molecules25235566 www.mdpi.com/journal/mole…”
MethodInfluentialProfound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967 · cited 1×
“It affects muscle and fat tissue and the liver, but not the polycystic ovary itself [39,40].”
BackgroundTeede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., & the International PCOS Network (2018) · Clinical Endocrinology · doi:10.1111/cen.13795 · Cited by 1,823
Research works printed but not linked: 4
- Ciotta, L., Iozza, I., Rubbino, G., Iemmola, A., Lizzio, I., Teodoro, M.C., and Palumbo, M. (2010, January 4–7). Treatment of hyperandrogenism by myo-inositol. Proceedings of the 14th World Congress of Gynecological Endocrinology, Firenze, Italy.
- Di Berardino, O.M., Monteleone, P., Valentino, V., Ruggiero, M., Papini, F., Cela, V., Artini, P.G., and Genazzani, A.R. (2010, January 4–7). Myo-inositol administration in pcos patients after IVF. Proceedings of the 14th World Congress of Gynecological Endocrinology, Firenze, Italy.
- Papaleo, E., De Santis, L., Baillargeon, J., Zacche, M., Fusi, F., Brigante, C., and Ferrari, A. (2008, January 6–9). Comparison of myo-inositol plus folic acid vs clomiphene citrate for first line treatment in women with polycystic ovary syndrome. Proceedings of the 24th Annual Meeting of ESHRE, Barcelona, Spain.
- Genazzani, 2020, Expert’s opinion: Integrative treatment with inositols and lipoic acid for insulin resistance of PCOS. Gynecol, Reprod. Endocrinol. Metab., 1, 146
Cited by
Contreras-Bolívar, V., García-Fontana, B., García-Fontana, C., & Muñoz-Torres, M. (2021) · Nutrients · doi:10.3390/nu13103491 · Cited by 226
Mitochondrial Dysfunction and Chronic Inflammation in Polycystic Ovary Syndrome
Dabravolski, S. A., Nikiforov, N. G., Eid, A. H., Nedosugova, L. V., Starodubova, A. V., Popkova, T. V., Bezsonov, E. E., & Orekhov, A. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083923 · Cited by 207
Calcaterra, V., Verduci, E., Cena, H., Magenes, V. C., Todisco, C. F., Tenuta, E., Gregorio, C., De Giuseppe, R., Bosetti, A., Di Profio, E., et al. (2021) · Nutrients · doi:10.3390/nu13061848 · Cited by 183
“Among them, inositol [166,167] has been shown to provide benefits for subjects with PCOS, improving IR and reducing the secretion of triglycerides.”
BackgroundPolycystic ovarian syndrome-current pharmacotherapy and clinical implications
Rashid, R., Mir, S. A., Kareem, O., Ali, T. F., Ara, R., Malik, A., Amin, F., & Bader, G. N. (2022) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2021.11.009 · Cited by 222
Inositols: From Established Knowledge to Novel Approaches
Dinicola, S., Unfer, V., Facchinetti, F., Soulage, C. O., Greene, N. D., Bizzarri, M., Laganà, A. S., Chan, S.-Y., Bevilacqua, A., Pkhaladze, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910575 · Cited by 154
“However, 25% to 75% of patients treated with myo-Ins may still be resistant to treatment [171].”
BackgroundSelf-citation
Metadata
- Authors
- Kamenov, Z., & Gateva, A.
- Affiliations
- Alexandrovska Hospital (BG)
- Corresponding author
- Kamenov, Zdravko
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-11-27
- Volume
- 25
- Issue
- 23
- Pages
- 5566
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7729761
- OpenAlex
- W3109824023
- Cited by
- 100
- References
- 147
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 15 · 2023: 29 · 2022: 14 · 2021: 12
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- polycystic ovary syndrome, myo-inositol, D-chiro-inositol, insulin resistance, hyperandrogenism, hirsutism, acne, ovulation induction, ovarian function, fertility, insulin signaling, metabolic outcomes
- MeSH terms
- Animals, Female, Humans, Inositol, Ovulation, Polycystic Ovary Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inositols in PCOS. https://app.cochat.ai/papers/10.3390/molecules25235566
- The paper
- Kamenov, Z., & Gateva, A. (2020). Inositols in PCOS. Molecules. https://doi.org/10.3390/molecules25235566
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.